安罗替尼治疗妇科恶性肿瘤的研究进展
Research Progress of Anlotinib for Treating Gynecologic Malignancies
摘要: 安罗替尼是我国正大天晴公司自主研发的一种小分子TKI，目前尚未获批适应证用于妇科肿瘤。有关于安罗替尼在妇科恶性肿瘤的临床研究正如火如荼进行中，部分研究已有数据上的更新。本文总结了目前安罗替尼单药及安罗替尼联合化疗、靶向、免疫等在妇科肿瘤的临床研究，为其在妇科肿瘤的临床应用提供依据。
Abstract: Anlotinib is a small molecule TKI developed independently by China’s Zhengda Tianqing Company, which has not yet been approved for indication in gynecologic tumors. Clinical studies on anlotinib in gynecologic malignancies are in full swing, and some of them have been updated with data. This article summarizes the current clinical studies of anlotinib alone and anlotinib in combination with chemotherapy, targeting and immunology in gynecologic tumors to provide a basis for its clinical application in gynecologic tumors.
文章引用：王焕焕, 赵红. 安罗替尼治疗妇科恶性肿瘤的研究进展[J]. 临床医学进展, 2023, 13(5): 8640-8647. https://doi.org/10.12677/ACM.2023.1351208

参考文献

[1] Zheng, R., Zhang, S., Zeng, H., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9. [Google Scholar] [CrossRef] [PubMed]
[2] 范典, 郑博豪, 周圣涛. 宫颈癌靶向治疗和免疫治疗研究进展[J]. 中国肿瘤临床, 2020, 47(21): 1100-1107.
[3] Menderes, G., Black, J., Schwab, C.L. and Santin, A.D. (2016) Immunotherapy and Targeted Therapy for Cervical Cancer: An Update. Expert Review of Anticancer Therapy, 16, 83-98. [Google Scholar] [CrossRef] [PubMed]
[4] 刘宏飞, 张海燕, 常学智, 等. 分子靶向药物治疗宫颈癌的研究进展[J]. 中国处方药, 2022, 20(6): 167-168.
[5] Gao, Y., Liu, P. and Shi, R. (2020) Anlotinib as a Molecular Targeted Therapy for Tumors. Oncology Letters, 20, 1001-1014. [Google Scholar] [CrossRef] [PubMed]
[6] Syed, Y.Y. (2018) Anlotinib: First Global Approval. Drugs, 78, 1057-1062. [Google Scholar] [CrossRef] [PubMed]
[7] Lin, B., Song, X., Yang, D., Bai, D., Yao, Y. and Lu, N. (2018) Anlotinib Inhibits Angiogenesis via Suppressing the Activation of VEGFR2, PDGFRβ and FGFR1. Gene, 654, 77-86. [Google Scholar] [CrossRef] [PubMed]
[8] Cheng, Y., Han, B., Li, K., et al. (2020) Effect of Anlotinib as a Third- or Further-Line Therapy in Advanced non-Small Cell Lung Cancer Patients with Different Histologic Types: Sub-group Analysis in the ALTER0303 Trial. Cancer Medicine, 9, 2621-2630. [Google Scholar] [CrossRef] [PubMed]
[9] Han, B., Li, K., Zhao, Y., et al. (2018) Anlotinib as a Third-Line Therapy in Patients with Refractory Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (ALTER0302). British Journal of Cancer, 118, 654-661. [Google Scholar] [CrossRef] [PubMed]
[10] 中国医师协会肿瘤医师分会, 中国临床肿瘤学会血管靶向治疗专家委员会, 中国抗癌协会肿瘤靶向治疗专业委员会. 盐酸安罗替尼治疗晚期非小细胞肺癌专家共识[J]. 中华医学杂志, 2018, 98(44): 3561-3567.
[11] Li, N., Wu, T., Hong, Y.G., et al. (2022) A Multi-Center, Single-Arm, Phase II Study of Anlotinib Plus Paclitaxel and Cisplatin as the First-Line Therapy of Recurrent/Advanced Esophageal Squamous Cell Carcinoma. BMC Medicine, 20, Article No. 472. [Google Scholar] [CrossRef] [PubMed]
[12] Liu, J., Gao, T., Tan, Z., et al. (2022) Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma. Clinical Cancer Research, 28, 3473-3479. [Google Scholar] [CrossRef] 
[13] Ma, J., Song, Y., Shou, J., et al. (2020) Anlotinib for Patients with Metastatic Renal Cell Carcinoma Previously Treated with One Vascular Endothelial Growth Factor Recep-tor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Frontiers in Oncology, 10, Article 664. [Google Scholar] [CrossRef] [PubMed]
[14] Li, D., Chi, Y., Chen, X., et al. (2021) Anlotinib in Locally Ad-vanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial. Clinical Cancer Re-search, 27, 3567-3575. [Google Scholar] [CrossRef] 
[15] Kong, T., Chen, L., Zhao, X., Duan, F., Zhou, H., Wang, L. and Liu, D. (2022) Anlotinib Plus Etoposide and Cisplatin/Carboplatin as First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Single-Arm, Phase II Study. Investigational New Drugs, 40, 1095-1105. [Google Scholar] [CrossRef] [PubMed]
[16] Sun, Y., Zhou, A., Zhang, W., et al. (2021) Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma: An Open-Label Phase II Study (ALTER-0802 Study). Hepatology International, 15, 621-629. [Google Scholar] [CrossRef] [PubMed]
[17] Chi, Y., Shu, Y., Ba, Y., et al. (2021) Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703). The Oncologist, 26, e1693-e703. [Google Scholar] [CrossRef] [PubMed]
[18] Hegde, P.S., Wallin, J.J. and Mancao, C. (2018) Predictive Markers of Anti-VEGF and Emerging Role of Angiogenesis Inhibitors as Immunotherapeutics. Seminars in Cancer Biology, 52, 117-124. [Google Scholar] [CrossRef] [PubMed]
[19] Carmeliet, P. and Jain, R.K. (2011) Molecular Mechanisms and Clinical Applications of Angiogenesis. Nature, 473, 298-307. [Google Scholar] [CrossRef] [PubMed]
[20] 黄伟, 解玉卓, 赵涵, 等. 安罗替尼抗肿瘤疗效的研究进展[J]. 实用药物与临床, 2019, 22(9): 990-993.
[21] 崔广华, 杨宇. 安罗替尼在晚期恶性肿瘤治疗中的研究进展[J]. 现代肿瘤医学, 2022, 30(16): 3032-3036.
[22] Xie, C., Wan, X., Quan, H., et al. (2018) Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor. Cancer Science, 109, 1207-1219. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, G., Sun, M., Jiang, Y., et al. (2019) Anlotinib, a Novel Small Mo-lecular Tyrosine Kinase Inhibitor, Suppresses Growth and Metastasis via Dual Blockade of VEGFR2 and MET in Oste-osarcoma. International Journal of Cancer, 145, 979-993. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, Q., Lai, Q., Jiang, Y., et al. (2022) Anlotinib Exerts Potent Antileukemic Activities in Ph chromOsome Negative and Positive B-Cell Acute Lymphoblastic Leukemia via Perturbation of PI3K/AKT/mTOR Pathway. Translational Oncology, 25, Article ID: 101516. [Google Scholar] [CrossRef] [PubMed]
[25] Yang, Q., Ni, L., Imani, S., et al. (2020) Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade. Cancer Management and Research, 12, 4937-4948. [Google Scholar] [CrossRef] 
[26] 陈彦民, 邹明雷, 李丽, 等. 安罗替尼通过上调miR-33b抑制PI3K/AKT信号通路来抑制HeLa增殖、迁移侵袭的作用机制[J]. 实用癌症杂志, 2022, 37(5): 706-711.
[27] Wang, H., Shan, B. and Tian, W. (2022) Anlotinib in Patients with Recurrent Platinum-Resistant or Platinum-Refractory Ovari-an Carcinoma: A Prospective, Single-Center, Single-Arm, Phase II Clinical Trial (033). Gynecologic Oncology, 166, S23. [Google Scholar] [CrossRef] 
[28] Liu, D., Yan, T. and Zhang, Q. (2021) Anlotinib Plus Chem-otherapy as First-Line Treatment for Advanced Ovarian Cancer: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study. Gynecologic Oncology, 162, S89-S90. [Google Scholar] [CrossRef] 
[29] 姚书娜, 姚志华, 严正, 等. 安罗替尼联合依托泊苷口服治疗铂类耐药或难治性晚期卵巢癌的临床疗效观察[J]. 中国医药导刊, 2021, 23(2): 100-103.
[30] Chen, J., Wei, W., Zheng, L., et al. (2021) Anlotinib Combined with Pemetrexed as a Further Treatment of Patients with Plati-num-Resistant Ovarian Cancer: A Single-Arm, Open-Label, Phase II Study. Gynecologic Oncology, 162, S61-S62. [Google Scholar] [CrossRef] 
[31] Liu, G., Feng, Y., Li, J., et al. (2022) A Novel Combo of Niraparib and Anlotinib in Platinum-Resistant Ovarian Cancer, the Final Efficacy and Safety Report of ANNIE Study, a Phase II, Multi-Center Trial (LBA 2). Gynecologic Oncology, 166, S47. [Google Scholar] [CrossRef] 
[32] Zhang, B., Lin, S., Peng, Y., et al. (2022) Anlotinib Com-bined with Niraparib Dual Therapy in Platinum-Resistant Recurrent Ovarian Clear Cell Carcinoma (CC-ANNIE): A Sin-gle-Center, Single-Arm, Phase 2 Trial (586). Gynecologic Oncology, 166, S284-S285. [Google Scholar] [CrossRef] 
[33] 金惠敏, 林丽红, 赵振, 等. 安罗替尼联合PD-1抑制剂后线治疗晚期上皮性卵巢癌的疗效及安全性分析[J]. 肿瘤防治研究, 2022, 49(10): 1059-1064.
[34] Lan, C.Y., Zhao, J., Yang, F., et al. (2022) Anlotinib Combined with TQB2450 in Patients with Platinum-Resistant or -Refractory Ovarian Cancer: A Multi-Center, Single-Arm, Phase 1b Trial. Cell Reports Medicine, 3, Article ID: 100689. [Google Scholar] [CrossRef] [PubMed]
[35] Zhu, J., Song, C., Zheng, Z., et al. (2021) Anlotinib in Chinese Patients with Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial. Frontiers in Oncology, 11, Article 720343. [Google Scholar] [CrossRef] [PubMed]
[36] 谭柳, 楚阿兰, 杨瑜, 等. 安罗替尼联合化疗在子宫颈癌进展期患者中的疗效与安全性观察[J]. 实用妇产科杂志, 2022, 38(4): 305-309.
[37] Xu, Q., Wang, J., Sun, Y., et al. (2022) Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. Journal of Clinical Oncology, 40, 1795-1805. [Google Scholar] [CrossRef] 
[38] Zheng, M., Zhou, Y., Zhou, J., et al. (2022) 564P Efficacy and Safety of Tislelizumab Plus Anlotinib in the Treatment of Cervical Cancer Resistant to Standard Therapy: A Prospective, Sin-gle-Arm, Open Labelled Phase II Clinical Trial. Annals of Oncology, 33, S806. [Google Scholar] [CrossRef] 
[39] Cui, Q., Mao, Y., Hu, Y., et al. (2022) Anlotinib in Recurrent or Metastatic Endometrial Cancer. International Journal of Gynecological Cancer, 32, 1147-1152. [Google Scholar] [CrossRef] [PubMed]
[40] Taurin, S., Yang, C.H., Reyes, M., et al. (2018) Endometrial Can-cers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated with a New Small Tyro-sine Kinase Inhibitor in an Orthotopic Mouse Model. International Journal of Gynecological Cancer, 28, 152-160. [Google Scholar] [CrossRef] 
[41] Miller, D., Miller, D.S., Cheung, E., et al. (2019) 1033P-Phase Ib/IIa Study Assessing the Safety and Efficacy of Adding AL3818 (Anlotinib) to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian or Cervical Carcinoma. Annals of Oncology, 30, v422. [Google Scholar] [CrossRef] 
[42] Wei, W., Ban, X., Yang, F., et al. (2022) Phase II Trial of Efficacy, Safety and Biomarker Analysis of Sintilimab Plus Anlotinib for Patients with Recurrent or Advanced Endo-metrial Cancer. Journal for Immunotherapy of Cancer, 10, e004338. [Google Scholar] [CrossRef] [PubMed]
[43] Wu, X., Liang, S., Chen, X., et al. (2022) 555P TQB2450 Injection Combined with Anlotinib Hydrochloride Capsule in the Treatment of Advanced, Recurrent or Metastatic Endometrial Cancer: A Multicohort, Open Label, Multicenter Phase II Clinical Trial—The TQB2450-II-08 Trial. Annals of Oncology, 33, S802. [Google Scholar] [CrossRef] 

为你推荐